Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Ras: Past, Present, and Future: Volume 153

Ras: Past, Present, and Future: Volume 153

O'Bryan, John P.
Piazza, Gary

Hardcover

Series: Advances in Cancer Research, Book 153

Medical ReferenceBiologyGenetics

ISBN10: 0128244852
ISBN13: 9780128244852
Publisher: Academic Press
Published: Feb 4 2022
Pages: 356
Weight: 1.42
Height: 0.81 Width: 6.00 Depth: 9.00
Language: English
Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once undruggable RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.

Also in

Medical Reference

View All